Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
BALANCE represents something structurally novel in CMMI's history: a federal drug purchasing cartel operating under section 1115A authority. CMS is not designing a care delivery model — it is inserting itself as a monopsonistic negotiating agent between pharmaceutical manufacturers and two payer classes (state Medicaid agencies and Part D sponsors), then using CMMI's waiver authority to override statutory exclusions that would otherwise block coverage. This is a significant regulatory innovation with lasting implications regardless of whether BALANCE itself succeeds.
The most consequential design choice is the coverage exclusion waiver. Section 1860D-2(e) of the Act explicitly prohibits Part D coverage of weight-loss agents. CMMI is waiving this provision under 1115A(d)(1) for participating plans — an exercise of administrative authority that has no prior precedent at this scale and will almost certainly face legal scrutiny. If upheld, it establishes that CMMI can unilaterally create new Part D drug benefit categories without Congressional action, a precedent with significant downstream implications for future models.
The Inflation Reduction Act interaction is the most technically complex design element. For drugs subject to Maximum Fair Prices (MFPs) under the Drug Price Negotiation Program — Ozempic® and Wegovy® are likely candidates — CMMI is waiving section 1860D-2(d)(1)(D) so that gross drug costs are based on WAC rather than MFP. Manufacturers then provide a rebate via a new "Facilitated DIR" (FAD) PDE field to bring the net price down to the negotiated GLP-1 Discounted Price of $245 per month supply. The structural implication: plans will have WAC-based gross costs on their PDEs, triggering standard MDP liability, while a separate manufacturer invoice through the Manufacturer Payment Portal reconciles back to $245 net. Plans running this through their actuarial models will find two distinct financial flows that must be tracked independently.
The 80% participation threshold for Medicare launch is a clever adverse selection mitigation mechanism, but it also creates a single point of failure. If plan applications fall below 80% of NAMBA-eligible beneficiary enrollment (calculated from February 2026 enrollment data), the Medicare component does not launch in 2027. This threshold — combined with the April 20, 2026 application deadline and April 30 notification date — means the model's Medicare viability was effectively decided in a 10-day window in spring 2026.
For Part D Plan Sponsors: The core financial proposition is acquiring GLP-1 coverage at $245/month net for drugs retailing at WAC prices of approximately $900–$1,100/month (based on published list prices for semaglutide and tirzepatide products). The gross-to-net spread is absorbed via manufacturer FAD rebates. Cost sharing for Enhanced Alternative plans caps at $50/28–30-day supply; AE/BA plans cap at $125. The deductible phase adds no more than $245 plus a dispensing fee for a 28–30-day fill.
The financial risk for plans centers on utilization uncertainty. A plan with 100,000 Medicare beneficiaries and a 5% uptake rate (5,000 users) faces approximately $14.7 million in annual gross drug costs at $245/month × 12 months × 5,000 users, before beneficiary cost-sharing offsets. At the $50 EA cost-sharing maximum, beneficiary contributions cover $3 million, leaving $11.7 million in plan/CMS liability to be split per the standard Part D payment structure. Plans that opt into the narrowed risk corridor (first threshold at ±2.5% vs. standard ±5%) gain meaningful financial protection if their model drug utilization rate exceeds one standard deviation above the mean for their plan type — a trigger determined post-plan-year, creating real-time actuarial uncertainty during the bid year.
For State Medicaid Agencies: The GLP-1 Discounted Price for Medicaid is confidential (Appendix B distributed via secure Box folder), but the model's savings hypothesis rests on supplemental rebates exceeding the MDRP statutory minimum. States that already have commercial semaglutide/tirzepatide SRAs for diabetes coverage must either terminate or amend those existing agreements before implementing model SRAs — an administrative burden that could delay FY 2026 savings realization for states with complex managed care alignment requirements. States choosing to start with FFS populations only (permitted under the phased approach) effectively bifurcate their drug coverage policy for up to 12 months, creating parity risk in managed care contract negotiations.
Key cash flow risk: Medicaid rebate reconciliation through T-MSIS and manufacturer invoicing runs on a quarterly lag. States that begin coverage May 1, 2026 may not see first rebate receipts until Q3 2026 at earliest, while drug expenditures begin immediately. Medicaid CFOs should model a 3–6 month negative cash flow exposure at model launch.
Advantaged: Large national MA-PD parent organizations. Plans with diversified plan type portfolios can manage the DS-plan conversion (to AE or BA) required for participation while maintaining network breadth. The participation threshold calculation rewards organizations that can commit large beneficiary volumes — a structural advantage for UnitedHealth, CVS/Aetna, Humana, and Elevance, all of which have sufficient plan diversity to hit the 90%-of-basic-plans enrollment requirement while absorbing the actuarial uncertainty.
Disadvantaged: Regional and single-state PDPs. These plans lack the actuarial depth to absorb utilization variance, may not qualify for the narrowed risk corridor (dependent on being ≥1 SD above mean — a relative metric that disadvantages plans with lower-income, higher-morbidity populations that may drive disproportionate uptake), and face disproportionate administrative costs for a single-state model implementation. The model's structure will likely accelerate consolidation among smaller PDP sponsors.
Medicaid managed care plans face a distinct pressure. State participants must ensure MCO drug policies align with model Key Terms — including the standardized prior authorization criteria — by January 1, 2027 for full participation. States that carve GLP-1s out of managed care risk creating FFS-only coverage islands that complicate care coordination. MCOs with capitated rates set before model implementation will find their medical loss ratios disrupted without corresponding rate adjustments, since GLP-1 costs for model-eligible indications were not incorporated into base actuarial assumptions.
Interaction with MSSP/ACO REACH: BALANCE has no explicit interaction with shared savings models. ACOs that have invested in metabolic health management programs may see their attributed beneficiaries accessing GLP-1s through Part D without ACO involvement in the prescribing or lifestyle support workflow — a leakage risk for ACOs betting on obesity management as a cost-reduction lever.
Physicians: The prior authorization criteria are clinically specific — BMI ≥35 (no comorbidity required), BMI ≥30 with HFpEF/uncontrolled HTN/CKD 3a+/OSA/MASH, or BMI ≥27 with pre-diabetes, prior MI, prior stroke, or symptomatic PAD. Provider attestation (not clinical documentation review) satisfies the PA requirement unless Auto-Lookback via ICD-10 codes succeeds. This is a relatively low documentation burden. However, prescribers must attest to lifestyle modification commitment — and the RFA explicitly states no step therapy related to lifestyle can be required — meaning practices will need to confirm that their PA workflows don't inadvertently impose such requirements through payer portals. Independent and small-group practices without dedicated prior authorization staff will benefit from the Auto-Lookback provision, but should not assume payers will implement it uniformly at model launch.
Health Systems: Systems with obesity medicine programs or endocrinology departments see expanded patient flow from newly covered GLP-1s across Medicaid and Medicare populations. The lifestyle support program — required to be funded by manufacturers at no cost to beneficiaries — is structured as a manufacturer-run digital/telephonic platform, not a health system service. This is a missed revenue opportunity for systems with established chronic disease management infrastructure. Health system strategists should proactively engage participating manufacturers about integration of the manufacturer lifestyle platform with health system care management workflows to capture attribution and quality performance data.
Hospitals: The model's long-run hypothesis — that GLP-1-driven metabolic improvement reduces hospitalizations for cardiovascular events, OSA complications, and diabetes-related admissions — is directionally correct but operates on a 3–7 year clinical timeline. Hospitals face a near-term volume reduction risk in elective metabolic and bariatric surgery if GLP-1 uptake is significant and sustained. Bariatric surgery programs should begin modeling patient volume scenarios under 10–20% diversion of surgical candidates to GLP-1 therapy. The model runs through December 31, 2031 — sufficient timeline for clinically meaningful utilization shifts.
MA Plans: Beyond the Part D financial mechanics described above, MA plans face a Star Ratings dimension. Medication adherence measures and chronic disease management outcomes — both affected by GLP-1 utilization — are weighted heavily in Star calculations. Plans that achieve strong model drug adherence rates (supported by the manufacturer lifestyle platform) may see meaningful Star score improvements, partially offsetting the actuarial uncertainty from utilization variance. MA plans should treat BALANCE participation as a Star strategy investment, not purely a pharmacy cost decision.
Bottom Line: BALANCE is structurally the most ambitious CMMI pharmaceutical intervention ever attempted, and its architecture — federal monopsony negotiation plus broad 1115A waiver authority — will define the boundaries of CMMI's authority for years. Organizations that engage early on PA workflow automation, managed care alignment, and lifestyle program integration will capture first-mover advantages. Those that wait for implementation clarity risk being locked into unfavorable operational postures as the model's 5-year performance period begins January 1, 2027.